Lorazepam
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Status Epilepticus
Conditions
Status Epilepticus
Trial Timeline
Nov 1, 2014 → Aug 1, 2016
NCT ID
NCT02239380About Lorazepam
Lorazepam is a phase 3 stage product being developed by Pfizer for Status Epilepticus. The current trial status is completed. This product is registered under clinical trial identifier NCT02239380. Target conditions include Status Epilepticus.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03905798 | Pre-clinical | Completed |
| NCT02239380 | Phase 3 | Completed |
Competing Products
9 competing products in Status Epilepticus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGM097 | Novartis | Phase 1 | 33 |
| BVS857 | Novartis | Phase 2 | 52 |
| Lorazepam | Pfizer | Pre-clinical | 22 |
| levetiracetam (add-on) | UCB | Phase 2 | 49 |
| ESES treated with clobazam | Lundbeck | Pre-clinical | 20 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Phase 1 | 30 |
| SAGE-547 | Supernus Pharmaceuticals | Pre-clinical | 18 |
| SAGE-547 | Supernus Pharmaceuticals | Phase 1/2 | 36 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 3 | 72 |